Low-dose menaquinone-4 improves γ-carboxylation of osteocalcin in young males: a non-placebo-controlled dose-response study

Nutr J. 2014 Aug 27;13:85. doi: 10.1186/1475-2891-13-85.

Abstract

Background: Menaquinone-4 is a type of vitamin K that has a physiological function in maintaining bone quality via γ-carboxylation of osteocalcin. However, little is known about the beneficial effect of intake of dosages below1500 μg/day.

Findings: Fifteen healthy males aged 25.0 years (median) participated in a non-placebo-controlled dose-examination study. They received menaquinone-4 daily for 5 weeks at 0, 300, 600, 900, and 1500 μg/day in weeks 1, 2, 3, 4, and 5, respectively. Compared with baseline, serum γ-carboxylated osteocalcin levels were significantly greater at an intake of 900 μg/day or more; serum undercarboxylated osteocalcin levels and the ratio of serum undercarboxylated osteocalcin to γ-carboxylated osteocalcin were significantly lower than baseline at doses of 600 μg/day or more.

Conclusions: This preliminary graded-dose study suggested that menaquinone-4 supplementation at 600 μg/day or more is likely to be important in terms of vitamin K requirements for bone health.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Body Mass Index
  • Body Weight
  • Bone and Bones / drug effects*
  • Bone and Bones / metabolism
  • Dietary Supplements*
  • Dose-Response Relationship, Drug
  • Healthy Volunteers
  • Humans
  • Male
  • Osteocalcin / blood*
  • Vitamin K 1 / blood
  • Vitamin K 2 / administration & dosage
  • Vitamin K 2 / analogs & derivatives*
  • Young Adult

Substances

  • Biomarkers
  • Osteocalcin
  • Vitamin K 2
  • menatetrenone
  • Vitamin K 1